5604 results
Refine Your Search
Analysis and Targeting of Tumor-Associated Monocytes/Macrophages that Inhibit PD-1 Blockade
Inhibition of a immune exhaustion pathway, termed blockade, enables immune effector cells to attack cancers. In classic Hodgkin Lymphoma (cHL), blo…
The Leukemia & Lymphoma Society Welcomes Five Members to Board of Directors
(Rye Brook, NY, July , ) - The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July , : Leroy M. Ball…
News Release
Matthew Frank
I am a and an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy (BMT&CT). Clinically, I care f…
Autologous CD22 CAR T cell Therapy for the Treatment of non-Hodgkin Lymphoma
CD19 targeting chimeric antigen receptor (CAR) T cell therapies (CAR19) are effective treatments for patients with Lymphoma (NHL), however, the major…
Armin Rashidi
I am an Associate Professor of Medicine (Hematology, Oncology, and Transplantation) at Fred Hutch with clinical trial and computational expertise.
Fecal microbiota transplantation to prevent acute GVHD after allogeneic stem cell transplantation
In up to half of patients with hematologic malignancies undergoing allogeneic stem cell transplantation, the trajectory of a smooth recovery toward cu…
Steven Treon
Steve Treon MD, PhD is a Senior Physician and the Director of the Bing Center for Waldenstrom’s Macroglobuliemia (WM) at the Dana Farber Cancer Instit…
Targeting mutated MYD88 pro-survival signaling in B-cell malignancies
Our laboratory and those of others discovered highly recurring mutations in the gene MYD88 which are found in patients with various cancers including…
Pharmacological strategies to enhance T- and NK-cell-based therapies in blood cancers
Although they represent a major therapeutic progress for blood cancers, cells and other based therapies are subject to eventual development of resis…
Towards Equity in Specialized Cancer Care for Adolescents and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Our study is designed to directly inform the pathways through which health insurance influences access to care at an SCC for individuals with AYA ALL …
Lori Muffly
Dr. Lori Muffly MD MS is an Associate Professor of Medicine at Stanford University in the Division of Blood and Marrow Transplantation and Cellular Th…
Meng Li
Dr. Meng Li is an Assistant Professor at the Department of Health Services Research at the UT MD Anderson Cancer Center and a nonresident fellow at th…
Investigating the Impact of Insurance Coverage on Access to Care and Outcomes among Lymphoma Patients
In this proposal we will investigate the association between insurance coverage and access to care, survival, and financial hardship among patients ac…
Oreofe Odejide
Dr. Odejide is a health services researcher, a hematologic oncologist at the Cancer Institute, and an Assistant Professor of Medicine at Harvard Medi…
Health Insurance and End-of-Life Care for People with Hematologic Malignancies
Patients with blood cancers from racial and ethnic minority groups are more likely to experience suboptimal (EOL) care. These disparities may be part…
Together Teens & 20s by St. Jude
Produced by St. Jude Children’s Research Hospital, Together by St. Jude is an online resource providing information and education for adolescents and …
Together by St. Jude
Produced by St. Jude Children’s Research Hospital, Together by St. Jude is an online resource providing information and education for families facing …
Why: A Memoir of Love and Lymphoma
There is no test of a couple’s bonds like the revelation that one of them has a disease. One of them, a husband, wife, or partner, will become a pati…
_dam_file_162296.jpg?v=70b47c66-3452-4c70-a4f7-782bc489f35f&crop=true&keep=c&w=400&h=400)
Honoring Blood Cancer Survivors
Throughout June, in commemoration of #NationalCancerSurvivorMonth, we at LLS have been highlighting the resilience and achievements of blood cancer su…
Designed biosensor to enhance CAR T cell therapy for multiple myeloma
We will develop a novel T cell therapy strategy for multiple myeloma (MM) that will combine existing chimeric antigen receptors (CARs) with a novel de…
Caroline Arber
Caroline Arber obtained her Doctor of Medicine from the University of Basel, Switzerland, and specialized in Internal Medicine and Hematology, with a …
Memory-like natural killer cells and venetoclax to eradicate measurable residual disease in AML
This proposal is to conduct a phase I (early phase) clinical trial to test whether the combination of the approved targeted therapy venetoclax with N…
Ruben Carrasco
Dr. Carrasco earned his MD and PhD degrees at the University of Chile. Motivated by his desire to practice medicine at the highest level, he immigrate…
Developing selective inhibitors of the b-catenin/BCL9 transcriptional complex for myeloma therapy
The /BCL9 transcriptional complex, is a novel dependency in multiple myeloma (MM). Disruption of this complex inhibits MM cell growth in culture and i…
Jing Yang
My research focuses on the translation of bench works into new therapeutic approaches/strategies for multiple myeloma and other blood cancers. One of …